Expansion of Frontline Immunotherapy Regimens Improves Prognosis, Increases Optimism in Urothelial Cancer
Peter H. O’Donnell, MD, provides insights on key developments in bladder cancer management and how they have generated optimism within the field.
EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer
Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.
Dr Siefker-Radtke on the Safety of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer
Arlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.
Dr Bellmunt on the Impact of Treatment With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer
Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.
ADCs and Immunotherapy Broaden the Bladder Cancer Treatment Paradigm
Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer.
Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur
Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis
Ponatinib Showcases Long-Term Efficacy, Safety in CP-CML With T315I Mutations
Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC
